GELS Company Profile and Key Details

GELS has shown mixed momentum, gaining 34.15% over the past week and -13.93% over the past quarter, though year-to-date performance is up 31.25%. Short-term trend indicators are bullishly aligned (SMA20 -7.35%, SMA50 -15.27%, SMA200 -43.31%). The stock’s 14-day RSI is 41.01 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.8% below its high and over 11.64% above its low. Average 10-day trading volume of 11.70 million shares is significantly above the 3-month average of 3.92 million, indicating heightened recent market interest.

Gelteq Limited Ordinary Shares has 10.03 million shares outstanding. The public float is 4.26 million shares, elevated short interest at 0.02% of float. This equals 1.15 thousand shares. The short ratio is 0.01 days. Institutional investors hold 2.44% of the float. Insiders own 56.81%.

Gelteq Limited Ordinary Shares last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.29. This means the shares are trading below this model’s fair value.

Gelteq Limited Ordinary Shares (NASDAQ:GELS) closed at $0.87 USD, losing -$0.17 (-16.28%) from the previous close of $1.04. The stock is currently mid-range between its 52-week high and low $0.39 and $2.02. With a market capitalization of about $7.99 million, Gelteq Limited Ordinary Shares is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.18). Key stats such as the average daily volume over the past year has been around 3.69 million shares, volume is running light vs its 52-week average. Headquartered in Caulfield, VIC, Gelteq Limited Ordinary Shares operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Nathan Jacob Givoni, the company employs approximately 7 people and listed since October 29, 2024. Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use.

Our AI price prediction model suggests that Gelteq Limited Ordinary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 17.15%, with price expected at $1.02 by July 06, 2026, within a range of $0.70 to $1.31 3-Month Outlook: Projected fall of -6.97%, reaching $0.81 by September 16, 2026, with a range of $0.71 to $0.92. 1-Year Outlook: Projected gain of 126.25%, with price at $1.97 by June 22, 2027, within a range of $1.87 to $2.06.

Gelteq Limited Ordinary Shares (NASDAQ:GELS) shares are up 31.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Gelteq Limited Ordinary Shares trading at a premium to the broader market with a P/E of 0.0. Our AI forecast model points to short-term strength (17.15% over two weeks), a medium-term fall (-6.97% over three months), and a longer-term gain (126.25% over one year), with expected trading ranges indicating moderate volatility.

Gelteq Limited Ordinary Shares trades at a P/E ratio of 0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 83.04 The P/FCF stands at -2.23, also above market averages.